BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced its board of ...

Chief Executive Tom Polen said he believes the separation would help differentiate BD in the medical-technology industry, and ...

GlobalData’s director of therapy research & analysis in medical devices says the new entity could make an attractive ...

According to the company, medical essentials and interventional lead the medical technology unit's business lines, bringing ...

After parting ways with its diabetes franchise nearly three years ago, BD is slimming down even further with a plan to divest ...

American medical technology (MedTech) company Becton Dickinson (BDX) plans to split from its bioscience and diagnostic ...

BD announced its board of directors has unanimously authorized BD management to pursue a plan to separate BD’s Biosciences and Diagnostic ...

BD (NYSE: BDX) announced that its board unanimously authorized management to pursue the separation of its Life Sciences ...

As the company pursues this transaction, BD will remain focused on execution and continue to operate the Biosciences and Diagnostic Solutions business and the other BD businesses in alignment with ...

The plan is to position the New BD as a differentiated MedTech leader and enable optimized investment to accelerate the innovation pipeline and ongoing margin enhancement through BD Excellence to ...

Becton Dickinson said it would focus on medtech and prioritize research, acquisitions and high-growth markets.